Oncolytic rhabdovirus

Abstract

Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.

We claim: 
     
         1 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an oncolytic Farmington rhabdovirus. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein said composition comprises 10 3  to 10 13  plaque forming units (pfu) of Farmington rhabdovirus. 
     
     
         3 . A method for treating cancer in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of  claim 1 . 
     
     
         4 . The method of  claim 3 , wherein the cancer is selected from the group consisting of lung cancer, head and neck cancer, breast cancer, cancer of the central nervous system, pancreatic cancer, prostate cancer, renal cancer, bone cancer, testicular cancer, cervical cancer, ovarian cancer, gastrointestinal cancer, lymphoma, lung cancer, colon cancer, melanoma, and bladder cancer 
     
     
         5 . The method of  claim 4 , wherein the cancer is selected from the group consisting of breast, central nervous system, melanoma, lung, ovarian, pancreatic, colon, prostate and renal cancer. 
     
     
         6 . The method of  claim 3 , wherein the cancer is metastatic. 
     
     
         7 . The method of  claim 3 , wherein the subject is a human. 
     
     
         8 . The method of  claim 3 , wherein the composition is administered by intraperitoneal, intravascular, intramuscular, intratumoral, subcutaneous or intranasal administration. 
     
     
         9 . The method of  claim 8 , wherein the composition is administered by intratumoral or intravascular administration. 
     
     
         10 . The method of  claim 3 , wherein the composition is administered multiple times. 
     
     
         11 . The method of  claim 3 , further comprising administering an additional anti-cancer therapy. 
     
     
         12 . The method of  claim 11 , wherein the additional anti-cancer therapy is chemotherapeutic, radiotherapeutic or immunotherapeutic. 
     
     
         13 . The method of  claim 11 , wherein the additional anti-cancer therapy comprises administering to the subject a second oncolytic virus. 
     
     
         14 . The method of  claim 13 , wherein the second oncolytic virus is a poxvirus, herpes virus, measles virus, paramyxovirus, adenovirus, alphavirus, parvovirus or rhabdovirus. 
     
     
         15 . The method of  claim 14 , wherein the second oncolytic virus is a vaccinia virus. 
     
     
         16 . A method for treating cancer in a subject comprising administering to the subject an effective amount of an oncolytic Faimington rhabdovirus. 
     
     
         17 . The method of  claim 16 , wherein the subject is administered between 10 3  and 10 13  plaque forming units (pfu) of Farmington rhabdovirus. 
     
     
         18 . The method of  claim 16 , wherein the cancer is selected from the group consisting of lung cancer, head and neck cancer, breast cancer, cancer of the central nervous system, pancreatic cancer, prostate cancer, renal cancer, bone cancer, testicular cancer, cervical cancer, ovarian cancer, gastrointestinal cancer, lymphoma, lung cancer, colon cancer, melanoma, and bladder cancer 
     
     
         19 . The method of  claim 18 , wherein the cancer is selected from the group consisting of breast, central nervous system, melanoma, lung, ovarian, pancreatic, colon, prostate and renal cancer. 
     
     
         20 . The method of  claim 16 , wherein the subject is a human.